<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Harrow Health Inc — News on 6ix</title>
<link>https://6ix.com/company/harrow-health-inc</link>
<description>Latest news and press releases for Harrow Health Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Mon, 27 Apr 2026 11:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/harrow-health-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo68357f7878dffbe2df0fb092.webp</url>
<title>Harrow Health Inc</title>
<link>https://6ix.com/company/harrow-health-inc</link>
</image>
<item>
<title>Harrow To Report First Quarter 2026 Financial Results After Market Close on May 11, 2026</title>
<link>https://6ix.com/company/harrow-health-inc/news/harrow-to-report-first-quarter-2026-financial-results-after-market-close-on-may-11-2026</link>
<guid isPermaLink="true">https://6ix.com/company/harrow-health-inc/news/harrow-to-report-first-quarter-2026-financial-results-after-market-close-on-may-11-2026</guid>
<pubDate>Mon, 27 Apr 2026 11:00:00 GMT</pubDate>
<description>Company to Host Conference Call to Discuss Results at 8:00 a.m. Eastern Time on May 12, 2026NASHVILLE, Tenn., April 27, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it will report its financial results for the first quarter ended March 31, 2026, on Monday, May 11, 2026, after the market close. The Company will also post its first quarter Letter to Stockholders to the “Investors” section of its</description>
</item>
<item>
<title>Harrow Announces the Issuance of J-Code for IOPIDINE® 1%</title>
<link>https://6ix.com/company/harrow-health-inc/news/harrow-announces-the-issuance-of-j-code-for-iopidiner-1percent</link>
<guid isPermaLink="true">https://6ix.com/company/harrow-health-inc/news/harrow-announces-the-issuance-of-j-code-for-iopidiner-1percent</guid>
<pubDate>Thu, 16 Apr 2026 04:00:00 GMT</pubDate>
<description>Reimbursement for Office-Based Utilization to Begin in July 2026 NASHVILLE, Tenn., April 16, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading</description>
</item>
<item>
<title>LogiCare3PL Selected as Distribution Partner by Harrow</title>
<link>https://6ix.com/company/harrow-health-inc/news/logicare3pl-selected-as-distribution-partner-by-harrow</link>
<guid isPermaLink="true">https://6ix.com/company/harrow-health-inc/news/logicare3pl-selected-as-distribution-partner-by-harrow</guid>
<pubDate>Tue, 14 Apr 2026 14:30:00 GMT</pubDate>
<description>LogiCare3PL today announced it has been selected by Harrow, Inc. (Nasdaq: HROW) as a distribution partner for Harrow's portfolio of ophthalmic disease management solutions. Effective February 1, 2026, LogiCare3PL is providing both non-title and 3PL title distribution services, supporting distribution of Harrow's products across the U.S. market.</description>
</item>
<item>
<title>Harrow Announces Pricing of $50.0 Million Offering of Senior Unsecured Notes Due 2030</title>
<link>https://6ix.com/company/harrow-health-inc/news/harrow-announces-pricing-of-dollar500-million-offering-of-senior-unsecured-notes-due-2030</link>
<guid isPermaLink="true">https://6ix.com/company/harrow-health-inc/news/harrow-announces-pricing-of-dollar500-million-offering-of-senior-unsecured-notes-due-2030</guid>
<pubDate>Tue, 24 Mar 2026 04:00:00 GMT</pubDate>
<description>NASHVILLE, Tenn., March 24, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America,</description>
</item>
<item>
<title>Harrow Announces Add-On Offering of $50.0 Million of Senior Unsecured Notes to Support Growth</title>
<link>https://6ix.com/company/harrow-health-inc/news/harrow-announces-add-on-offering-of-dollar500-million-of-senior-unsecured-notes-to-support-growth</link>
<guid isPermaLink="true">https://6ix.com/company/harrow-health-inc/news/harrow-announces-add-on-offering-of-dollar500-million-of-senior-unsecured-notes-to-support-growth</guid>
<pubDate>Tue, 24 Mar 2026 04:00:00 GMT</pubDate>
<description>NASHVILLE, Tenn., March 24, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America,</description>
</item>
<item>
<title>Harrow Announces Three Abstracts Accepted for Presentation at ASCRS 2026 Annual Meeting</title>
<link>https://6ix.com/company/harrow-health-inc/news/harrow-announces-three-abstracts-accepted-for-presentation-at-ascrs-2026-annual-meeting</link>
<guid isPermaLink="true">https://6ix.com/company/harrow-health-inc/news/harrow-announces-three-abstracts-accepted-for-presentation-at-ascrs-2026-annual-meeting</guid>
<pubDate>Wed, 18 Mar 2026 04:00:00 GMT</pubDate>
<description>NASHVILLE, Tenn., March 18, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America,</description>
</item>
<item>
<title>Harrow to Present at Leerink Partner’s 2026 Global Healthcare Conference</title>
<link>https://6ix.com/company/harrow-health-inc/news/harrow-to-present-at-leerink-partners-2026-global-healthcare-conference-7</link>
<guid isPermaLink="true">https://6ix.com/company/harrow-health-inc/news/harrow-to-present-at-leerink-partners-2026-global-healthcare-conference-7</guid>
<pubDate>Wed, 04 Mar 2026 05:00:00 GMT</pubDate>
<description>NASHVILLE, Tenn., March 04, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America,</description>
</item>
<item>
<title>Harrow to Initiate Phase 3 Clinical Trial Seeking to Expand TRIESENCE® Label to Include Ocular Inflammation and Pain Following Cataract Surgery Indication</title>
<link>https://6ix.com/company/harrow-health-inc/news/harrow-to-initiate-phase-3-clinical-trial-seeking-to-expand-triesencer-label-to-include-ocular-inflammation-and-pain-following-cataract-surgery-indication</link>
<guid isPermaLink="true">https://6ix.com/company/harrow-health-inc/news/harrow-to-initiate-phase-3-clinical-trial-seeking-to-expand-triesencer-label-to-include-ocular-inflammation-and-pain-following-cataract-surgery-indication</guid>
<pubDate>Tue, 03 Mar 2026 05:00:00 GMT</pubDate>
<description>NASHVILLE, Tenn., March 03, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America,</description>
</item>
<item>
<title>Harrow Announces Q4 and Full-Year 2025 Financial Results and 2026 Financial Guidance</title>
<link>https://6ix.com/company/harrow-health-inc/news/harrow-announces-q4-and-full-year-2025-financial-results-and-2026-financial-guidance</link>
<guid isPermaLink="true">https://6ix.com/company/harrow-health-inc/news/harrow-announces-q4-and-full-year-2025-financial-results-and-2026-financial-guidance</guid>
<pubDate>Mon, 02 Mar 2026 21:05:00 GMT</pubDate>
<description>Fourth Quarter, Full-Year 2025 and Selected Highlights: Record quarterly revenue of $89.1 million, a 33% increase over $66.8 million recorded in the prior-year periodFull-Year revenue of $272.3 million, a 36% increase over $199.6 million recorded in 2024GAAP net income of $6.6 million in Q4 2025, and net loss $5.1 million for 2025Adjusted EBITDA of $24.2 million in Q4 2025, and $61.9 million for 2025Generated $43.9 million of operating cash flow in 2025, versus $(22.2) million used in operations</description>
</item>
<item>
<title>Harrow To Report Fourth Quarter and Year-End 2025 Financial Results After Market Close on March 2, 2026</title>
<link>https://6ix.com/company/harrow-health-inc/news/harrow-to-report-fourth-quarter-and-year-end-2025-financial-results-after-market-close-on-march-2-2026</link>
<guid isPermaLink="true">https://6ix.com/company/harrow-health-inc/news/harrow-to-report-fourth-quarter-and-year-end-2025-financial-results-after-market-close-on-march-2-2026</guid>
<pubDate>Wed, 18 Feb 2026 12:00:00 GMT</pubDate>
<description>Company to Host Conference Call to Discuss Results at 8:00 a.m. Eastern Time on March 3, 2026NASHVILLE, Tenn., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it will report its financial results for the fourth quarter and year ended December 31, 2025, on Monday, March 2, 2026, after the market close. The Company will also post its fourth quarter Letter to Stockholders to the “Investors”</description>
</item>
<item>
<title>Harrow Announces Cash-Pay Direct-to-Prescriber PharmaPack™ Kits</title>
<link>https://6ix.com/company/harrow-health-inc/news/harrow-announces-cash-pay-direct-to-prescriber-pharmapacktm-kits</link>
<guid isPermaLink="true">https://6ix.com/company/harrow-health-inc/news/harrow-announces-cash-pay-direct-to-prescriber-pharmapacktm-kits</guid>
<pubDate>Tue, 17 Feb 2026 12:00:00 GMT</pubDate>
<description>PharmaPack Program to Expand Access to Affordable, FDA-Approved Branded Ophthalmic TherapiesNASHVILLE, Tenn., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced the launch of a new Direct-to-Prescriber (DTP) cash-pay offering called PharmaPack, which expands the Company’s commitment to offering affordable FDA-approved branded products as alternatives to off-label compounded formulations. PharmaP</description>
</item>
<item>
<title>Harrow Reaffirms 2025 Full-Year Revenue Guidance of $270–$280 Million, Marking Another Year of Strong Growth</title>
<link>https://6ix.com/company/harrow-health-inc/news/harrow-reaffirms-2025-full-year-revenue-guidance-270-280-million-marking-another-year</link>
<guid isPermaLink="true">https://6ix.com/company/harrow-health-inc/news/harrow-reaffirms-2025-full-year-revenue-guidance-270-280-million-marking-another-year</guid>
<pubDate>Mon, 02 Feb 2026 05:00:00 GMT</pubDate>
<description>Doubling of VEVYE® Sales Force is On Track, Expansion of IHEEZO® Commercial Footprint to the Office-Based Setting Underway, and Doubling TRIESENCE® Commercial</description>
</item>
<item>
<title>Harrow to Present at Two Investor Conferences in December</title>
<link>https://6ix.com/company/harrow-health-inc/news/harrow-present-two-investor-conferences-december-2025-11-24</link>
<guid isPermaLink="true">https://6ix.com/company/harrow-health-inc/news/harrow-present-two-investor-conferences-december-2025-11-24</guid>
<pubDate>Mon, 24 Nov 2025 05:00:00 GMT</pubDate>
<description>NASHVILLE, Tenn., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America,</description>
</item>
<item>
<title>Harrow Announces Closing of Acquisition of Melt Pharmaceuticals</title>
<link>https://6ix.com/company/harrow-health-inc/news/harrow-announces-closing-acquisition-melt-pharmaceuticals-2025-11-18</link>
<guid isPermaLink="true">https://6ix.com/company/harrow-health-inc/news/harrow-announces-closing-acquisition-melt-pharmaceuticals-2025-11-18</guid>
<pubDate>Tue, 18 Nov 2025 05:00:00 GMT</pubDate>
<description>NASHVILLE, Tenn., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America,</description>
</item>
<item>
<title>Harrow Announces Third Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/harrow-health-inc/news/harrow-announces-third-quarter-2025-financial-results-2025-11-10</link>
<guid isPermaLink="true">https://6ix.com/company/harrow-health-inc/news/harrow-announces-third-quarter-2025-financial-results-2025-11-10</guid>
<pubDate>Mon, 10 Nov 2025 05:00:00 GMT</pubDate>
<description>Third-Quarter 2025 and Recent Selected Highlights: Total revenues of $71.6 million, a 45% increase over $49.3 million recorded in the prior-year periodGAAP</description>
</item>
<item>
<title>Harrow To Report Third Quarter 2025 Financial Results After Market Close on November 10, 2025</title>
<link>https://6ix.com/company/harrow-health-inc/news/harrow-report-third-quarter-2025-financial-results-after-market-close-november-10</link>
<guid isPermaLink="true">https://6ix.com/company/harrow-health-inc/news/harrow-report-third-quarter-2025-financial-results-after-market-close-november-10</guid>
<pubDate>Mon, 27 Oct 2025 04:00:00 GMT</pubDate>
<description>Company to Host Conference Call to Discuss Results at 8:00 a.m. Eastern Time on November 11, 2025 NASHVILLE, Tenn., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Harrow</description>
</item>
<item>
<title>ImprimisRx Announces Leadership Changes</title>
<link>https://6ix.com/company/harrow-health-inc/news/imprimisrx-announces-leadership-changes-2025-10-06</link>
<guid isPermaLink="true">https://6ix.com/company/harrow-health-inc/news/imprimisrx-announces-leadership-changes-2025-10-06</guid>
<pubDate>Mon, 06 Oct 2025 04:00:00 GMT</pubDate>
<description>Frank Mullery Appointed Chief Executive Officer of ImprimisRx Bridseida Cruz Appointed Head of Quality of ImprimisRx NASHVILLE, Tenn., Oct. 06, 2025 (GLOBE</description>
</item>
<item>
<title>Harrow to Acquire Melt Pharmaceuticals</title>
<link>https://6ix.com/company/harrow-health-inc/news/harrow-acquire-melt-pharmaceuticals-2025-09-26</link>
<guid isPermaLink="true">https://6ix.com/company/harrow-health-inc/news/harrow-acquire-melt-pharmaceuticals-2025-09-26</guid>
<pubDate>Fri, 26 Sep 2025 04:00:00 GMT</pubDate>
<description>NASHVILLE, Tenn., Sept. 26, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America,</description>
</item>
<item>
<title>Harrow Launches Harrow Access for All (HAFA)</title>
<link>https://6ix.com/company/harrow-health-inc/news/harrow-launches-harrow-access-all-hafa-2025-09-25</link>
<guid isPermaLink="true">https://6ix.com/company/harrow-health-inc/news/harrow-launches-harrow-access-all-hafa-2025-09-25</guid>
<pubDate>Thu, 25 Sep 2025 04:00:00 GMT</pubDate>
<description>HAFA to Expand Harrow’s Innovative Market Access Model Across Ophthalmic Portfolio Program will be available in late 2025 through the HarrowAccess.com Portal</description>
</item>
<item>
<title>Harrow Announces Agenda and Speakers for Investor & Analyst Day</title>
<link>https://6ix.com/company/harrow-health-inc/news/harrow-announces-agenda-and-speakers-investor-analyst-day-2025-09-15</link>
<guid isPermaLink="true">https://6ix.com/company/harrow-health-inc/news/harrow-announces-agenda-and-speakers-investor-analyst-day-2025-09-15</guid>
<pubDate>Mon, 15 Sep 2025 04:00:00 GMT</pubDate>
<description>NASHVILLE, Tenn., Sept. 15, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America,</description>
</item>
</channel>
</rss>